Biopharma Gains Another Shot on Goal With IND Approval

Research Report
  ()
The firm's CD19- and CD3-targeting monoclonal antibody is now cleared for evaluation in a Phase I clinical trial, noted an H.C. Wainwright & Co. report.

Former Investment Officer of One of the World's Largest Sovereign Wealth Funds Shares His Current Focus

  ()
Streetwise Reports sat down with Řyvind Schanke, the chief investment officer of TD Veen and the former investment officer of one of the world's largest sovereign wealth funds as he shares his current focus.

Med Tech Co. Well-Poised for Revenue Growth This Year

Research Report
  ()
New revenue sources already in place are expected to boost cash flow 72% over the next 12 months, noted an H.C. Wainwright & Co. report.

Biotech's Novel Thin Formulation Improves Veteran-Aiding Treatment

  ()
This morning Awakn Life Sciences announced further details regarding its August 2022 announcement that it had "signed a twelve-month option agreement with a leading drug development, manufacturing, and delivery systems company to in-license a proprietary formulation and route of administration for ketamine." Read to learn more about this announcement, the benefits of this treatment, and what analysts and experts are saying about the company.

Biopharma Creating COVID Drug Gets US$8.2M From the DOD

Research Report
  ()
This tranche, other cash and cash equivalents, and current cash flow are sufficient to get the developer of immunotherapeutics through 2023, noted an H.C. Wainwright & Co. report.

Exploring Why The Economist Named this Biotech 'One To watch' in 2023

  ()
As more researchers delve into the medicinal potentials of once-verboten compounds, forward-thinking companies like Awakn Life Sciences Corp. are leading the charge to map their most useful aspects and open access for people who need help now. Read more to learn what catalysts Awakn has in store and why The Economist touched on this treatment as one of their top stories of 2023.

Telehealth Co. Expects More Growth in 2023

  ()
Officials at telemedicine company Reliq Health Technologies say they expect to accelerate growth "significantly" in 2023, which could lead to a share buyback program.

Biopharma Co.'s Burn Tissue Removal Product Approved

Research Report
  ()
Because of the green light from the U.S. Food and Drug Administration, H.C. Wainwright & Co. raised its target price on the developer of this drug, according to a recent report.

Which Precious Metal Has Chen Excited for 2023?

  ()
It's valued the world over as a precious metal, and now it's in demand for the green economy. Which element has asset manager Chen Lin looking forward to the New Year?

Tech. Analyst Says Pharma Co. Is at a Favorable Risk/Reward Ratio

Contributed Opinion
  ()
Technical analyst Clive Maund reviews Algernon Pharmaceuticals Inc.'s 6-month, 3-year, and 9-year charts to tell you whether you should be interested in this pharma company.

Target Price Boosted 400% on Biopharma Co.

Research Report
  ()
The immunotherapy developer also announced positive initial results from the VITALIZE trial in diffuse large B cell lymphoma, noted an H.C. Wainwright & Co. report.

Biotech at Good Entry Point for Investors, Analyst Says

Research Report
  ()
The company, focused on psychedelic-assisted psychotherapies to better treat addiction, is worth more than the CA$10 million the market is valuing it at, noted a Stifel report.
Tags:  Psychedelics

Data on New Cell Therapy for LBCL Encouraging, Analyst Says

Research Report
  ()
The biopharma behind the investigational treatment plans to advance it into a potentially pivotal clinical program next year, noted a BTIG report.

Why One Fund Owns 13% of This Small-Cap Pharma

  ()
Clinical-stage Algernon Pharmaceuticals' multiple pipelines include testing a psychedelic for the treatment of stroke, and testing other drugs for idiopathic pulmonary fibrosis and chronic kidney disease.

Expert Investing Ideas

"Positive Phase 2a data were achieved with AGN's ifenprodil."

–Dr. André Uddin, Research Capital Corporation


"AGN is rated a Buy again here."

–Clive Maund, CliveMaund.com


"AGN is rated an immediate Strong Buy."

–Clive Maund, CliveMaund.com


"This is a good time to buy PMN stock."

–Clive Maund, CliveMaund.com


"AGN is rated Buy again here."

–Clive Maund, CliveMaund.com


"AGN has the capacity to make really big moves."

–Clive Maund, CliveMaund.com


Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Target Price Boosted on Canadian Pharma Co.

Research Report
  ()
This company, undergoing a business model shift, is doing well and remains Buy rated despite a weaker-than-expected Q3/22, noted a Research Capital Corp. report.

Expert Says Health Tech Co. Is in Another Buy Spot

Contributed Opinion
  ()
Expert Clive Maund reviews the 1-year chart for Reliq Health Technologies to tell you why he believes it is in another buy spot.

Biopharma Co. Now at a Bargain Price, Analyst Says

Research Report
  ()
Recent share price weakness and a catalyst-rich next six months are good news for investors, noted a Research Capital Corp. report.